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with a history of recurrent hospitalizations. Interventions targeted at preventing 
HF hospitalizations would be beneficial.
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Objectives: The objective of the study is to estimate the follow up cost and its com-
ponents in patients subjected to pacemaker (PM) and implantable cardioverter-defi-
brillator (ICD) implantation. MethOds: A single-center, prospective, study which 
was conducted for one year’s reriod. In total, 464 consecutive patients were recruited 
(370 were subjected to PM implantation, from which 240 initials, 130 replacements 
and 94 to ICD implantation, from which 80 initials, 14 replacements). Resource 
data were assessed at patients’ enrolment in the study and at 6th and 12th months 
of patients’ follow-up. Then, the annual patients’ follow up costs were calculated 
using the bottom-up approach. Results: The annual follow up cost for the patients 
who were subjected to PM implantation (initial or replacement) was found to be: 
The mean direct health care cost (outpatient visits, hospitalizations, medication 
use and the cost of laboratory and imagining diagnostic examinations) was € 1.386 
(€ 1.069-€ 1.962). The mean direct non-health care cost was € 359 (€ 207-€ 551). Finally 
the mean indirect cost was € 71 (€ 70-€ 72). The mean (95% confidence interval) total 
annual follow-up cost for the patients who were subjected to PM implantation was 
€ 1.816 (€ 1.433– € 2.421). The annual follow up cost for the patients were subjected 
to ICD implantation (initial or replacement) was found to be: The mean direct health 
care cost (outpatient visits, hospitalizations, medication use and the cost of labo-
ratory and imagining diagnostic examinations) was 2.279 (1743-3.081). The mean 
direct non-health care costs was € 173 (€ 11-€ 386). Finally the mean indirect cost 
was € 367 (€ 72-€ 802). The mean (95% confidence interval) total annual follow-up 
cost for the patients who were subjected to ICD implantation was € 2.819 (€ 2.115–€ 
3.703). cOnclusiOns: The study provides unique data regarding the follow up 
cost and its separate components of patients with CRMDs in Greece. Moreover the 
findings indicate a low annual follow-up cost.
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Objectives: Limited evidence exists on the burden of chronic heart failure (CHF) 
in terms of reduced vs. preserved ejection fraction (HFrEF vs. HFpEF) and NYHA 
classification. This study aims to determine health care resource utilization asso-
ciated with CHF, both for HFrEF (≥ 45%) and HFpEF (< 40%) and according to NYHA 
class. MethOds: Retrospective analysis of a longitudinal population-based medical 
records database from southwestern Ontario was conducted. Records contain chart-
abstracted information such as diagnosis, physician visits and consultation notes. 
Data of adult patients with CHF diagnosed between Jan 1st, 2005 and Sept 31st, 2012 
with at least 1 year follow-up were included. Health care resources consumed by 
patients were identified in terms of hospitalizations, physician and emergency room 
visits and medical procedures. Data reported as mean values. Results: Records 
of 8,983 patients were included: 39% with HFrEF, 49% with HFpEF and 12% with an 
ejection fraction between 40-45%. The median follow-up duration was 51.6 months. 
Most patients were in NYHA class II (30%) or class III (34%) followed by class I (22%) 
and class IV (14%). In comparison to the HFpEF cohort, total hospitalizations (3.0 vs. 
4.2); including CHF hospitalizations (1.6 vs. 1.9), ER visits (2.1 vs. 3.1), GP visits (5.5 
vs. 6.1), specialist visits (3.0 vs. 3.2), lab tests (5.8 vs. 7.7) and medical procedures 
(3.9 vs. 4.1) were numerically higher for the HFrEF cohort. Among patients in NYHA 
class II-IV (N= 7006), hospitalizations (total: 4.5; CHF-related: 2.1) and lab tests (7.7) 
were numerically higher for class IV patients as was the frequency of GP visits (7.1) 
for class III patients. ER and specialist visits and medical procedures were similar 
across all NYHA classes. cOnclusiOns: In a real-world Canadian setting, patients 
with HFrEF and those in NYHA class III-IV seem to experience greater resource use 
which is consistent with the existing literature.
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Objectives: The objective of the present study is to estimate the procedure (or 
implantation) cost, which includes: the human resources cost, the implant and 
the supplies cost and the total hospitalization cost which includes: the procedure 
cost, the hospitalization cost, the laboratory and imaging diagnostic examination 
cost and the indirect cost, in patients subjected to pacemaker (PM) and implantable 
cardioverter-defibrillator (ICD) implantation. MethOds: A single-centre, prospec-
tive study was conducted for one year’s period. In total, 464 consecutive patients 
were recruited (370 were subjected to PM implantation initial or replacement and 94 
to ICD implantation initial or replacement). Resource data were assessed at patients’ 
enrolment in the study as well as during the procedure of implantation. Then, the 
components of the procedure cost and total hospitalization cost were calculated 
using the bottom-up approach. Results: The mean (95% confidence interval) pro-
cedure cost of PM and ICD implantation (including the costs of devices, electrodes, 
other supplies, and personnel’s time) was calculated to be € 1.803 (€ 1.758–€ 1.858) and 
€13.521 (€ 13.153–€13.892), respectively. The mean total hospitalization cost (includ-
ing procedure cost, hospitalization cost, cost of laboratory and imaging diagnostic 
examinations and the indirect cost attributed to productivity lost due to patient’s 
hospitalization) was € 3.926 (€ 3.711–€ 4.167) for PM and € 17.764 (€ 16.852–€ 18.692) for 
ICD. cOnclusiOns: These data revealed that although these devices are associ-
ated with a relatively high upfront cost, the total implantation cost for the society 
is relatively low compared with other countries. Therefore, implantation of such 
devices should be encouraged since these devices reduce the morbidity and mortal-
ity without a high economic burden to society.
CardioVasCUlar disorders – Patient-reported outcomes & Patient Prefer-
ence studies
PCV100
imPaCt oF ProVider mailinGs on mediCation adHerenCe in mediCare 
Part d members
Qiu Y.1, Borah B.J.2, Gleason P.1
1Prime Therapeutics LLC, Eagan, MN, USA, 2Mayo Clinic, Rochester, MN, USA
Objectives: Medication non-adherence is associated with worsening health out-
comes and higher medical costs. This study assessed the impact of a prescriber 
mailing intervention on adherence among 802,355 members enrolled in Medicare 
Part D prescription drug plans offered by a pharmacy benefit manager. MethOds: 
Non-adherent members in three drug classes – oral antidiabetics, statins and one 
class of antihypertensives (RAS antagonists) – were identified if their specific drug 
class proportion of days covered (PDC) was < 80% in a 12-month baseline period 
(2010Q4-2011Q3). Letters were mailed to their prescribers suggesting they discuss 
potential adherence barriers with their patients. Post-mailing PDC was calculated 
during a 12-month follow-up period after the mailing date. Members were included 
if they were age 18+, had 2 or more fills within the drug class, and were continu-
ously enrolled in the prescription drug plan during the baseline and follow-up peri-
ods. A historical control cohort was constructed using the same eligibility criteria 
as applied to the intervention cohort but no letter was mailed to the prescribing 
physicians. Multivariate logistic regression was used to model post-mailing adher-
ence (PDC≥ 80%), adjusting for age, gender, zip code level income, education and 
race variables. Analyses were conducted separately for each drug class. Results: 
Final analyzable members included 21,044 (Intervention= 10,707; Control= 10,337) 
for antidiabetics, 106,829 (Intervention= 53,957; Control= 52,872) for statins, and 
73,560 (Intervention= 36,706; Control= 36,854) for RAS antagonists. The baseline 
PDCs between the intervention and control cohorts were not statistically differ-
ent for all the three drug cohorts. Adjusted logistic regression results indicate the 
prescriber mailing was associated with significant adherence improvement, odds 
ratio (OR) 1.11 (95% confidence interval [CI], 1.05-1.18), OR 1.16 (95% CI, 1.13-1.19), 
and OR 1.07 (95% CI, 1.03-1.10) within the antidiabetic, statin and RAS antagonist 
drug classes, respectively. cOnclusiOns: Health plans should consider utilizing 
prescriber mailings in efforts to improve medication adherence for chronic diseases.
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Objectives: To analyze patient compliance towards their prescribed medication 
and to evaluate the patient knowledge regarding use of drugs. MethOds: The study 
was conducted in a tertiary care hospital in Pakistan. A random sample of 200 
patients was selected. The questionnaire was administered by trained interviewers 
in the Urdu language for ease of understanding by the patient. The questionnaire 
extracted information regarding patient demographics, life style (smoking, drink-
ing, physical activities), awareness about and characteristics of hypertension and 
anti-hypertensive treatment and factors that, in the patient’s views, encouraged or 
discouraged the patient’s drug taking behavior. Results: According to analysis, 81% 
patients were from urban areas and 19% patients were from rural areas. Most (71%) 
of the patients belonged to the age group of 40-50 years. Majority of the affected 
persons were male i.e. 70%, whereas females were 30%. The patients with history of 
CVS disorders in their families were 36%. It was found that 36% of the patients were 
smokers, 2% were drinkers and 75% had no physical activity in routine. The patients 
went for regular follow up of their blood pressure were 38.5% and 53% of the patients 
had regular lab tests during their treatment. It was found that 74.5% of patients used 
to take medication on time while 64% stopped their medication when they felt bet-
ter. The major reason (27.5%) for not taking medication was found to be the use of 
alternative medicines while 60% patients tried to clarify their doubts about therapy. 
Majority of patients (81.5%) followed precautionary measures, 21% patients used 
different reminders and 30.5% patients had difficulty in taking their medication. 
On felling worse 40% of the patients stopped taking medication. cOnclusiOns: 
There is need for educational intervention and patient counseling to understand 
the importance of compliance for this disease.
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Objectives: Single pill combinations (SPC) are associated with improved adher-
ence and persistence in hypertensive (HTN) populations. The evidence is not 
available for three drug SPC Exforge HCT. This study investigated if Exforge HCT 
is associated with improved 12-month persistence and adherence in adult hyper-
